Cargando…

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

BACKGROUND: The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea. METHODS: Patients with unresectable histologically confirmed metas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenhua, Xu, Jianming, Shen, Lin, Liu, Tianshu, Guo, Weijian, Zhang, Wen, Chen, Zhiyu, Zhu, Xiaodong, Li, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300831/ https://www.ncbi.nlm.nih.gov/pubmed/25527007 http://dx.doi.org/10.1186/1471-2407-14-986

Ejemplares similares

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
por: Burge, M E, et al.
Publicado: (2006)

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
por: Vasile, E, et al.
Publicado: (2009)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
por: Bazarbashi, Shouki, et al.
Publicado: (2015)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
por: Garcia-Alfonso, P, et al.
Publicado: (2009)

A prospective phase II study of raltitrexed combined with S‐1 as salvage treatment for patients with refractory metastatic colorectal cancer
por: Huang, Mingzhu, et al.
Publicado: (2021)

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study
por: Klautke, G, et al.
Publicado: (2006)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
por: Zhang, Xiaowei, et al.
Publicado: (2022)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
por: Matsuda, Chu, et al.
Publicado: (2022)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study
por: Li, Wenhua, et al.
Publicado: (2016)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off
por: Li, Jin, et al.
Publicado: (2017)

Development of phimosis as an adverse drug reaction to capecitabine with irinotecan
por: Patel, Priyeshkumar, et al.
Publicado: (2022)

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
por: Zhao, Xiaoying, et al.
Publicado: (2023)

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
por: Zarate, R, et al.
Publicado: (2010)

CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
por: Cai, Gang, et al.
Publicado: (2015)

Combination effects of capecitabine, irinotecan and 17-AAG on colorectal cancer cell line (HT-29)
por: Zeynali-Moghaddam, Shima, et al.
Publicado: (2022)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study
por: Liu, Xiu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c0ll2lnkpkd42mq8m4ukmc5ds4